Past Acquisition Anacor was acquired by Pfizer in 2016 for approximately $5.2 billion, indicating a successful exit and potential access point for follow-on deals, licensing, or integration opportunities with Pfizer’s broader portfolio.

BorOn Platform The company leveraged a boron chemistry platform to discover and develop small-molecule therapeutics, suggesting a niche capability that could be attractive for partnerships or licensing in specialized drug discovery programs.

Financial Scale With revenue disclosed in the range of $50M-$100M and total funding around $448M, there is a signal of a moderate-capitalized biotech asset with room for co-development or equity-backed collaborations to advance pipeline programs.

Pipeline Opportunities Given the historical focus on novel small molecules and the Pfizer acquisition context, identify opportunities to license or co-develop late-stage assets or Phase 2/3 candidates either through Pfizer’s network or other large pharma seeking bolt-on innovations.

Strategic Fit Potential partners could align with large pharma seeking niche chemistry platforms or specialty small-molecule candidates that complement cardiovascular, dermatology, infectious disease, or oncology portfolios, leveraging Anacor’s proven exit and Boron chemistry expertise.